Bevacizumab is a drug that blocks angiogenesis, the growth of new blood vessels. It is used to treat various cancers, including colorectal, lung, and kidney cancer, and eye disease. Bevacizumab is a humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A). VEGF-A is a chemical signal that stimulates angiogenesis in a variety of diseases, especially in cancer, retinal proliferation of diabetes in the eye. Bevacizumab was the first clinically available angiogenesis inhibitor in the United States. Bevacizumab is currently approved by the U...